Core Viewpoint - The Guangdong Provincial Development and Reform Commission has issued an action plan to accelerate the high-quality development of the nuclear medicine industry from 2025 to 2030, aiming for significant improvements in innovation capabilities, key technology breakthroughs, and the establishment of a competitive nuclear medicine industry cluster by 2030 [1][3]. Industry Development - The nuclear medicine industry is experiencing unprecedented growth opportunities due to global aging populations, rising chronic disease rates, and continuous technological innovations [2]. - Recent favorable policies at both national and local levels are propelling the rapid development of the nuclear medicine industry in China, with a focus on enhancing innovation capabilities and expanding application fields [3]. Market Size - According to a report by Zhongyan Puhua Industry Research Institute, the global nuclear medicine market is expected to exceed $100 billion by 2025, with a compound annual growth rate of over 10%, potentially reaching over $200 billion by 2030 [4]. Company Developments - Companies in the nuclear medicine sector are actively advancing their positions, with Shanghai United Imaging Healthcare Co., Ltd. recently obtaining a patent for a scanning method for nuclear medicine devices [5]. - Qingdao Baiyang Pharmaceutical Co., Ltd. announced that its radiopharmaceutical, a first-class new drug in China, has successfully met key clinical trial endpoints, addressing significant challenges in tumor imaging diagnostics [5]. Challenges - The nuclear medicine field faces challenges due to high technical barriers and strict regulatory policies, requiring substantial investment in research and development to overcome technological bottlenecks [6]. - Market awareness of nuclear medicine products is relatively low, and the high costs associated with these technologies pose additional challenges for widespread adoption [6].